NAA60 (HAT4): the newly discovered bi-functional Golgi member of the acetyltransferase family

Clinical Epigenetics

Table 2 Acetyltransferases involvement in disease outcomes

Name	Target	Disease	References
MYST1	NFR2	Non-small-cell lung cancer	[68]
	EGFR	Glioblastoma	[48]
	TGFβ	Fibrosis	[49]
Tip60	Neural plasticity genes	Neuronal disease	[69]
Tip60	DNA repair genes	Breast cancer	[70]
MYST2	β-catenin	Alzheimer’s disease	[71]
MYST2	MLLX	Acute myeloid leukaemia	[72]
MYST3	KAT6a/MYST3	Syndromic developmental delay	[73]
MYST4	MAPK	Noonan syndrome-like phenotype	[52]
MYST4	MYST4 OE	High-grade serous carcinoma	[75]
GCN5	GCN5 OE	Hepatocellular carcinoma	[76]
GCN5	Egr-1, E2F1, Bim	Brain injuries	[76]
p300/CBP	cAMP-PKA, p53, ER	Lung cancer	[123]
NAT10	CEP170	Multiple myeloma	[60]
NatA	β-catenin /cyclin D1, HIf1a, TSC2/mTOR, E-cadherin, p21, PIX/Cdc42/Rac1, MLCK, DNMT1	Cancer	[79]
NatB	Tropomyosin, CDK2, Hippo/YAP, ERK1/2	Hepatocellular carcinoma	[84]
NatD	Slug	Lung cancer	[67]
NatF	INFα	Influenza A virus	[103]

The acetylated targets and the diseases related to compromised acetylation are reported

ISSN: 1868-7083